Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.61 |
| ▸ | F13A1 | P00488 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TGM1 | P22735 | 1/20 | 0.56 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997535 | 0.84 | TGM2 (0.61) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL16653882 | 0.82 | TGM2 (0.59) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL440756 | 0.82 | TGM2 (0.63) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL439369 | 0.81 | TGM2 (0.79) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL1191835 | 0.80 | TGM2 (0.61) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL16242100 | 0.80 | TGM2 (0.61) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL29718235 | 0.80 | TGM2 (0.61) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL12265208 | 0.79 | THRA (0.63) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL10012411 | 0.79 | TGM2 (0.51) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL25293287 | 0.79 | TGM2 (0.59) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | claimed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| EP-3256132-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | TGM2 981/4885F13A1 2855/4885LMNA 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.